The Outcome of Six Patients with COVID-19 Infection and Multiple Myeloma.

Elsabah, Hesham; Aldapt, Mahmood B; Taha, Ruba; Soliman, Dina S; Elomri, Halima; Ibrahim, Feryal

Elsabah, Hesham; Aldapt, Mahmood B; Taha, Ruba; Soliman, Dina S; Elomri, Halima; Ibrahim, Feryal.

Afiliação

Elsabah H; Division of Hematology, Department of Medical Oncology, National Center for Cancer Care & Research (NCCCR), Hamad Medical Corporation (HMC), Doha, Qatar.
Aldapt MB; Division of Hematology, Department of Medical Oncology, National Center for Cancer Care & Research (NCCCR), Hamad Medical Corporation (HMC), Doha, Qatar.
Taha R; Division of Hematology, Department of Medical Oncology, National Center for Cancer Care & Research (NCCCR), Hamad Medical Corporation (HMC), Doha, Qatar.
Soliman DS; Department of Laboratory Medicine and Pathology, National Centre for Cancer Care & Research (NCCCR), Hamad Medical Corporation (HMC), Doha, Qatar.
Elomri H; Department of Laboratory Medicine and Pathology, Weill Cornell Medical College (WCMC-Q), Doha, Qatar.
Ibrahim F; Clinical pathology department, National Cancer Institute, Cairo-Egypt.

Mediterr J Hematol Infect Dis ; 12(1): e2020082, 2020.

Article em En | MEDLINE | ID: mdl-33194156

Palavras-chave

ARDS (acute respiratory distress syndrome); COVID-19; Interlukin6 (IL-6); Multiple myeloma (MM); Tocilizumab

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Mediterr J Hematol Infect Dis Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Qatar País de publicação: Itália

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google